Biocon founder Kiran Mazumdar Shaw says she is confident that the company’s investment and capacity expansion in Insulin will make the company the top hub for the drug in the next five years. She speaks in an exclusive conversation with Bloomberg’s Haslinda Amin. (Source: Bloomberg)
Trending
- UK air traffic control problem strands hundreds of thousands of passengers | Airline industry
- Trump administration has ‘profound concern’ over Ford ties to China
- Bank Secrecy Act/Anti-Money Laundering: Frequently Asked Questions Regarding Treatment of Verifiable Digital Credentials Under the Customer Identification Program Rule
- Copper CEO Amar Kuchinad departs as search for a buyer enters a fourth month
- Memory chips have come to rule the AI boom. Why Micron’s reign could be here to stay.
- LIV Golf files for Chapter 11 bankruptcy protection
- Hedge funder Brian Kelly built Bracket22 to be powered entirely by AI
- ‘I’m the executor’: My two siblings and I inherited an IRA. Can we just cash it out?
Wednesday, September 9
